Exane Derivatives’s Akebia Therapeutics AKBA Stock Holding History

Exane Derivatives’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$166	Hold	471	–	–	﹤0.01%	686
2022 Q1	$338	Hold	471	–	–	﹤0.01%	912
2021 Q4	$1.06K	Hold	471	–	–	﹤0.01%	703
2021 Q3	$1.36K	Hold	471	–	–	﹤0.01%	830
2021 Q2	$1.57K	Hold	471	–	–	﹤0.01%	833
2021 Q1	$1.59K	Hold	471	–	–	﹤0.01%	698
2020 Q4	$1.32K	Hold	471	–	–	﹤0.01%	659
2020 Q3	$1.18K	Hold	471	–	–	﹤0.01%	604
2020 Q2	$6.4K	Hold	471	–	–	﹤0.01%	433
2020 Q1	$3.57K	Hold	471	–	–	﹤0.01%	472
2019 Q4	$3.52K	Hold	471	–	–	﹤0.01%	459
2019 Q3	$1.85K	Hold	471	–	–	﹤0.01%	498
2019 Q2	$2.28K	Hold	471	–	–	﹤0.01%	502
2019 Q1	$3.86K	Hold	471	–	–	﹤0.01%	420
2018 Q4	$2.6K	Buy	+471	New	+$3.69K	﹤0.01%	513

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Exane Derivatives's AKBA Position: Q2 2022 in Review

Exane Derivatives held its Akebia Therapeutics (AKBA) position steady in Q2 2022 at 471 shares worth $166. The position accounts for ﹤0.01% of the portfolio, ranked #686.

Exane Derivatives first reported a position in AKBA in Q4 2018 and has held it in 15 quarters since. The position peaked at $6.4K in Q2 2020. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

Exane Derivatives held 471 shares of Akebia Therapeutics worth $166 as of Q2 2022.
Exane Derivatives left its Akebia Therapeutics share count unchanged in Q2 2022.
Akebia Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #686 holding.
Exane Derivatives first reported a position in Akebia Therapeutics in Q4 2018 and has held it in 15 quarters since.
Exane Derivatives's Akebia Therapeutics position peaked at $6.4K in Q2 2020.
96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.